Company Profile
3D Medicines Inc., a biopharmaceutical company researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the People's Republic of China.
The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors.
It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC, and TMB-H advanced cancer In Phase II clinical trials G/GEJ, EC, HCC, CRC, NSCLC, microsatellite stable CRC, and dMMR advanced sold tumors
Products which is in development pipeline include 3D189 for multi-indication tumor that has completed Phase I and is in phase III clinical trial for the treatment of acute myeloid leukemia (AML).
Its portfolio also includes 3D1001 for the treatment of post-surgical dental pain/cancer pain which is in phase II trial, 3D1002 for cancer pain/osteoarthritis and is in phase II trial, 3D229 (GAS6/AXL) for the treatment of acute myeloid leukemia (AML), kidney cancer, pancreatic cancer, breast cancer, lung cancer, ovarian cancer, and prostate cancer and has completed phase I clinical trial, 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy that is in Phase I clinical trial, 3D011 for advanced malignant solid tumor which is in Phase I clinical trial, 3D1015 for the treatment of metastatic castration-resistant prostate cancer which is in Phase I clinical trial, and 3D057, 3D059, 3D124, and 3D062 for multiple indications tumors which are in Phase I clinical trial. Founded in 2014, 3D Medcines is headquartered in Qingdao, China.